Free Trial

PetMed Express (NASDAQ:PETS) Issues Earnings Results

PetMed Express logo with Retail/Wholesale background

PetMed Express (NASDAQ:PETS - Get Free Report) released its earnings results on Monday. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.02), RTT News reports. PetMed Express had a negative return on equity of 1.00% and a negative net margin of 0.37%.

PetMed Express Trading Up 8.2 %

Shares of PETS stock traded up $0.34 during trading hours on Thursday, hitting $4.47. The company's stock had a trading volume of 395,715 shares, compared to its average volume of 289,990. The company has a 50 day moving average of $5.11 and a 200 day moving average of $4.32. The stock has a market cap of $92.35 million, a PE ratio of -74.50 and a beta of 0.70. PetMed Express has a 12-month low of $2.90 and a 12-month high of $6.85.

Analysts Set New Price Targets

Separately, StockNews.com downgraded shares of PetMed Express from a "buy" rating to a "hold" rating in a report on Tuesday.

Read Our Latest Analysis on PETS

Insider Activity at PetMed Express

In other news, Director Leslie C.G. Campbell bought 15,000 shares of the firm's stock in a transaction that occurred on Wednesday, December 4th. The stock was purchased at an average cost of $5.38 per share, for a total transaction of $80,700.00. Following the purchase, the director now directly owns 70,000 shares in the company, valued at approximately $376,600. This trade represents a 27.27 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.10% of the company's stock.

PetMed Express Company Profile

(Get Free Report)

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.

Featured Stories

Earnings History for PetMed Express (NASDAQ:PETS)

Should You Invest $1,000 in PetMed Express Right Now?

Before you consider PetMed Express, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PetMed Express wasn't on the list.

While PetMed Express currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
The EXACT Date of Next Stock Market Crash
HIMS Stock Up 120%! More Growth Ahead?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines